- Home
- ATAT vs GRFS Comparison
ATAT vs GRFS Comparison
Compare ATAT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAT | GRFS |
|---|---|---|
| Founded | 2013 | 1940 |
| Country | China | Spain |
| Employees | N/A | 25247 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.4B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATAT | GRFS |
|---|---|---|
| Price | $33.44 | $7.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $49.00 | $10.15 |
| AVG Volume (30 Days) | ★ 1.2M | 607.3K |
| Earning Date | 05-13-2026 | 07-28-2022 |
| Dividend Yield | ★ 2.06% | 1.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.48 | $4.49 |
| Revenue Next Year | $18.11 | $6.42 |
| P/E Ratio | $26.11 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.81 | $7.39 |
| 52 Week High | $43.17 | $11.14 |
Technical Indicators
Market Signals| Indicator | ATAT | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 41.27 |
| Support Level | $31.89 | $7.44 |
| Resistance Level | $39.19 | $8.24 |
| Average True Range (ATR) | 1.27 | 0.16 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 22.82 | 24.07 |
Price Performance
Historical ComparisonAbout ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.